My watch list  


Systematic (IUPAC) name
CAS number 500287-72-9
ATC code  ?
PubChem 6451164
Chemical data
Formula C22H18N6 
Mol. mass 366.42 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 38 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes Oral

Rilpivirine (TMC278) is a diarylpyrimidine under under investigation as a treatment for HIV infection. It is a non-nucleoside reverse transcriptase inhibitor with many times the potency of current available agents in that class, such as efavirenz.[1][2]It is expected to be FDA approved as soon as 2009.[3]


  1. ^ Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B (2006). "Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects". AIDS 20 (13): 1721–6. doi:10.1097/ PMID 16931936.
  2. ^ Pozniak A, Morales-Ramirez J, Mohap L et al. 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. Oral abstract 144LB.
  3. ^ Steve Mitchell. HIV Market To Top 10 Billion Dollars. United Press International. April 11, 2007.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rilpivirine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE